48
16.
Bateman ED et al. Global Strategy
for Asthma Management and Pre-
vention: GINA Executive Summary
Eur Resp J. 2008; Jan 31(1):143-178.
17.
David BK et al. Stinging Insect Al-
lergy. American Family Physician
2003; 67:398-403.
18.
WHO Expert Committee on Biologi-
cal Standardization: “Guidelines for
the preparation and stablishment of
reference materials and reference
reagents for biological substantes”.
WHOTech. Rep. Ser. 626; 1978.
19.
Neske F et al. BSP090 – the follow
up of CREATE. Arb Paul Ehrlich Ins
Bundesinstitut Impfstoffe biomedi-
nische Arzneimittel 2009; 96:12-20.
20.
Lorenz AR et al. The principle of ho-
mologous groups in regulatory af-
fairs of allergen products: a propos-
al. Int Arch Allergy Immunol 2008;
148(1):1-17.
21.
Englert L et al. El reglamento de
terapia con alérgenos. Paul Eh-
rlich Institute, Langen. Bundesge-
sundheitsbel 2012; 55:351-357. DOI
10.007/s00103-011-1434-7.
22.
WHO Position Paper. Allergy 1998;
44(53):5-42.
8.
Global Data “Allergic Rhinitis – Pipe-
line Assesment and Market Forecast
2017”. July 2010.
9.
EMA:
CHMP/BWP/304831/2007.
GUIDELINE ON ALLERGEN PROD-
UCTS: PRODUCTION AND QUALI-
TY ISSUES London Nov. 20. 2008.
10.
IUIS.
11.
ALLERGOME.
me.org
12.
SDAP.
13.
EFSA Journal 2004; 32:1-197.
14.
International Consensus (ICON) on
Drug Allergy. Pascal Demoly, Frank-
lin Adquinson, Knut Brockow, Mar-
iana Castell, Anca M Chiriac, Paul
A Greenberger, David A Khan, Da-
vid M Lang, Hae-Sim Park, Werner
Pichler, Mario Sánchez-Borges,Tet-
suoShiohara, BernardYu-HorThong
The International Collaboration in
Asthma, Allergy and Immunology
(iCAALL) 2012 by EAACI, AAAAI,
ACAAI, WAO. Allergy 2013.
15.
Demoly P et al. Epidemiology and
causes of Drug Hypersensitivity.
Pichler WJ (ed): Drug Hypersensi-
tivity. Basel, Karger, 2007:2-17.
Regulación sanitaria de los alérgenos
